Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes.

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2020-10-13 DOI:10.2217/hep-2020-0022

Ana-Maria Bucalau, Illario Tancredi, Martina Pezzullo, Raphael Leveque, Simona Picchia, Jean-Luc Van Laethem, Gontran Verset

{"title":"Balloon-occluded chemoembolization for hepatocellular carcinoma: a prospective study of safety, feasibility and outcomes.","authors":"Ana-Maria Bucalau, Illario Tancredi, Martina Pezzullo, Raphael Leveque, Simona Picchia, Jean-Luc Van Laethem, Gontran Verset","doi":"10.2217/hep-2020-0022","DOIUrl":null,"url":null,"abstract":"Aim: Evaluation of safety and efficacy of selective balloon-occluded transarterial chemoembolization using polyethylene glycol embolizing microspheres in patients with hepatocellular carcinoma.Materials & methods: Twenty-four consecutive patients were included in this monocentric prospective trial. Adverse events were evaluated at 24 h and 1 month. Imaging response according to modified response evaluation criteria in solid tumors was assessed at 1, 3 and 6 months.Results: The median time of follow-up was of 22.8 months (interquartile range (IQR) 17.38-26.22). Clinical grade 1/2 toxicities (0% >grade 2) were reported in 25.7% of patients, with abdominal pain being the most frequent complication (17.1%). No 30-days mortalities or liver decompensation were observed. The 1-month follow-up MRI showed an overall response rate of 74.3%.Conclusion: Balloon-occluded transarterial chemoembolization was shown to be safe and effective.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"8 1","pages":"HEP31"},"PeriodicalIF":1.2000,"publicationDate":"2020-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2020-0022","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/hep-2020-0022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 5

Abstract

Aim: Evaluation of safety and efficacy of selective balloon-occluded transarterial chemoembolization using polyethylene glycol embolizing microspheres in patients with hepatocellular carcinoma.

Materials & methods: Twenty-four consecutive patients were included in this monocentric prospective trial. Adverse events were evaluated at 24 h and 1 month. Imaging response according to modified response evaluation criteria in solid tumors was assessed at 1, 3 and 6 months.

Results: The median time of follow-up was of 22.8 months (interquartile range (IQR) 17.38-26.22). Clinical grade 1/2 toxicities (0% >grade 2) were reported in 25.7% of patients, with abdominal pain being the most frequent complication (17.1%). No 30-days mortalities or liver decompensation were observed. The 1-month follow-up MRI showed an overall response rate of 74.3%.

Conclusion: Balloon-occluded transarterial chemoembolization was shown to be safe and effective.

Abstract Image

查看原文本刊更多论文

肝细胞癌球囊闭塞化疗栓塞:安全性、可行性和结果的前瞻性研究。

目的:评价聚乙二醇微球选择性球囊栓塞经动脉化疗栓塞治疗肝癌患者的安全性和有效性。材料与方法:这项单中心前瞻性试验纳入了24例连续患者。不良事件分别于24小时和1个月进行评估。分别在1个月、3个月和6个月时，根据改进的疗效评价标准评估实体瘤的影像学疗效。结果:中位随访时间为22.8个月(四分位间距(IQR) 17.38 ~ 26.22)。25.7%的患者报告了临床1/2级毒性(0% > 2级)，腹痛是最常见的并发症(17.1%)。未见30天死亡或肝脏失代偿。1个月的随访MRI显示总有效率为74.3%。结论:球囊闭塞经动脉化疗栓塞是安全有效的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.